Mediastinal irradiation in combined modality therapy for Hodgkin's disease Journal Article


Authors: Dowling, S. W.; Peschel, R. E.; Portlock, C. S.; Kramer, C.; Farber, L. R.; Knowlton, A. H.
Article Title: Mediastinal irradiation in combined modality therapy for Hodgkin's disease
Abstract: Patients with Hodgkin's disease who present with large mediastinal masses in the setting of either early or advanced stage disease are frequently treated with combined modality therapy. Policies for radiation dose to the mediastinum in these settings range from no radiation to doses in the 3600-4000 cGy range. We reviewed the charts of 50 patients treated with radiation therapy following remission induction with chemotherapy between 1979 and 1983 to determine whether the dose of radiation to the mediastinum could be correlated with mediastinal control, relapsefree, and overall survival. Patients were divided into groups with small (SM, 30 pts.) and large (LM, 20 pts.) mediastinal masses and analyzed according to whether they had received low dose (LD, ≤2500 cGy) or high dose (HD, >2500 cGy) radiation to the mediastinum. The 5-year relapse-free survival (RFS) for all 50 patients was 84% (±8%, 95% confidence limits). For the patients with small mediastinal masses, 5-year RFS was 81% ± 20%, and for the patients with large mediastinal masses, 89% ± 16%. No clear dose-response effect was observed when the outcomes of the low dose and high dose patients were compared. This was true even in the patients with large mediastinal masses although the high dose subset of this group included patients felt to be at a higher risk for relapse following chemotherapy. Nine of eleven patients with large mediastinal masses treated with chemotherapy and low dose radiation remain disease-free. There was only one isolated mediastinal relapse in the entire group of patients. Treatment was well tolerated with no acute treatment-related deaths. Two patients developed second malignancies. We conclude that combined modality therapy using low dose radiation results in excellent 5-year relapse-free survival for most small and many large mediastinal mass patients, and that it is not necessary to treat all chemotherapy patients who present with mediastinal disease with high dose radiation to achieve these relapsefree survival rates. © 1990.
Keywords: adult; cancer chemotherapy; survival rate; retrospective studies; major clinical study; prednisone; doxorubicin; combined modality therapy; methodology; dacarbazine; antineoplastic combined chemotherapy protocols; radiotherapy dosage; radiotherapy; vincristine; chlormethine; procarbazine; vinblastine; hodgkin disease; bleomycin; mediastinal neoplasms; mediastinum cancer; hodgkin's disease; human; male; female; priority journal; article; mediastinal involvement
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 19
Issue: 3
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 1990-09-01
Start Page: 543
End Page: 546
Language: English
DOI: 10.1016/0360-3016(90)90479-4
PUBMED: 2211202
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Carol Portlock
    204 Portlock